Rznomics Partners with Eli Lilly to Pioneer RNA Editing Therapies for Hearing Loss Rznomics and Eli Lilly have signed a transformative agreement to develop RNA editing therapies aimed at treating sensorineural hearing loss, potentially worth over $1.3 billion.

Rznomics Partners with Eli Lilly to Pioneer RNA Editing Therapies for Hearing Loss #South_Korea #Rznomics #Seongnam #Eli_Lilly #RNA_Therapy

Rznomics Secures Fast Track Designation for Liver Cancer Treatment Drug RZ-001 Rznomics' anticancer drug RZ-001 receives Fast Track Designation from the FDA for liver cancer treatment, marking a significant milestone.

Rznomics Secures Fast Track Designation for Liver Cancer Treatment Drug RZ-001 #South_Korea #Cancer_Treatment #Rznomics #RZ-001 #Seongnam

Rznomics Launches Expanded Access Program for Glioblastoma Therapy RZ-001 Rznomics has announced the launch of its Expanded Access Program for RZ-001, an innovative therapy for Glioblastoma patients, offering new hope.

Rznomics Launches Expanded Access Program for Glioblastoma Therapy RZ-001 #South_Korea #Rznomics #RZ-001 #Glioblastoma #Seongnam